Affiliation:
1. Departments of Surgery Loyola University Chicago Stritch School of Medicine Maywood Illinois USA
2. Departments of Cancer Biology Loyola University Chicago Stritch School of Medicine Maywood Illinois USA
Abstract
AbstractLenvatinib is a tyrosine kinase inhibitor that prevents the formation of new blood vessels namely by inhibiting tyrosine kinase enzymes as the name suggests. Specifically, Lenvatinib acts on vascular endothelial growth factor receptors 1−3 (VEGFR1−3), fibroblast growth factor receptors 1−4 (FGFR1−4), platelet‐derived growth factor receptor‐alpha (PDGFRα), tyrosine‐kinase receptor (KIT), and rearranged during transfection receptor (RET). Inhibition of these receptors works to inhibit tumor proliferation. It is through these inhibition mechanisms that Lenvatinib was tested to be noninferior to Sorafenib. However, resistance to Lenvatinib is common, making the positive effects of Lenvatinib on a patient's survival null after resistance is acquired. Therefore, it is crucial to understand mechanisms related to Lenvatinib resistance. This review aims to piece together various mechanisms involved in Lenvatinib resistance and summarizes the research done so far investigating it.
Subject
Cancer Research,Molecular Biology
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献